Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ingevity (NGVT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Ingevity (NGVT) over the last 11 years, with Q3 2025 value amounting to $9.2 million.

  • Ingevity's Change in Accured Expenses fell 612.24% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year increase of 581.4%. This contributed to the annual value of -$1.0 million for FY2024, which is 8701.3% up from last year.
  • Ingevity's Change in Accured Expenses amounted to $9.2 million in Q3 2025, which was down 612.24% from -$9.8 million recorded in Q2 2025.
  • Ingevity's Change in Accured Expenses' 5-year high stood at $22.6 million during Q3 2022, with a 5-year trough of -$25.8 million in Q1 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was $700000.0 (2024), whereas its average is -$110526.3.
  • In the last 5 years, Ingevity's Change in Accured Expenses surged by 61200.0% in 2021 and then plummeted by 150000.0% in 2025.
  • Quarter analysis of 5 years shows Ingevity's Change in Accured Expenses stood at -$4.8 million in 2021, then rose by 6.25% to -$4.5 million in 2022, then tumbled by 271.11% to -$16.7 million in 2023, then skyrocketed by 45.51% to -$9.1 million in 2024, then soared by 201.1% to $9.2 million in 2025.
  • Its Change in Accured Expenses stands at $9.2 million for Q3 2025, versus -$9.8 million for Q2 2025 and $1.6 million for Q1 2025.